Ranibizumab

A4DAB218 | Ophthalmic disorders | Approved
VEGFA
G1 / None
Genentech Manhattan Eye Ear & Throat Hospital Novartis Ophthalmics University of Bonn
Approved
Fab
ACCENTRIX RG-3645 RG3645 RG 3645 RG-6321 RG6321 RG 6321 Susvimo
5.5
IMGT PubChem (46506960) PubChem (50070212) PubChem (103771523) PubChem (135321230) PubChem (178103385) PubChem (329976995) PubChem (348994288) PubChem (438447952) PubChem (441072530) PubChem (445534060) PubChem (461629174) PubChem (463561824) PubChem (468804000) PubChem (472217550) PubChem (472397235) PubChem (481101819) PubChem (481155378) PubChem (488418370) PubChem (508644634) PubChem (513262135) PubChem (519837115) Thera-SAbDab YAbS
Avg A4D Score
-0.6784
Score Range
-0.71 to -0.64
Structures
8
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB218_1cz8_H_L 1cz8 100% -0.6603 6.5 4.0 -0.0949 -0.7345
A4DAB218_1bj1_H_L 1bj1 97% -0.6886 6.5 4.0 -0.1696 -0.7567
A4DAB218_7v5n_B_A 7v5n 97% -0.6788 6.5 4.0 -0.3101 -0.7267
A4DAB218_6bft_H_L 6bft 96% -0.7047 6.5 4.0 -0.3845 -0.7469
A4DAB218_6bft_A_B 6bft 96% -0.713 6.5 4.0 -0.3946 -0.754
A4DAB218_7v5n_F_E 7v5n 97% -0.6761 6.5 4.0 -0.2723 -0.7296
A4DAB218_1cz8_Y_X 1cz8 100% -0.6636 6.5 4.0 -0.0974 -0.7379
A4DAB218_1bj1_K_J 1bj1 97% -0.6424 6.5 4.0 -0.171 -0.7042